129 unknown. 129 Phase 2, 15 Phase 1, 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 129 | Unknown 129 |
| Phase 1 | 15 | Unknown 15 |
| Phase 3 | 8 | Unknown 8 |
Follow Nervous System Neoplasms: new trials by email Literature Review of Nervous System Neoplasms trials Research Report on Nervous System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery FG001 prior to surgery - Low-grade Glioma, Meningioma | Phase 2 | Unknown | Copenhagen University Hospital, Rigshospitalet | 40 | 2024-05-01 | 2024-11-12 |
| SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases SHR-A1921 + Bevacizumab - TNBC, Brain Metastasis | Phase 2 | Unknown | Fudan University | 24 | 2024-02-01 | 2024-01-18 |
| SGM-101 in Colorectal Brain Metastases. SGM-101 - Rectal Neoplasms, Rectum Cancer | Phase 2 | Unknown | Leiden University Medical Center | 10 | 2024-01-01 | 2024-05-09 |
| Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases Cadonilimab - Non Small Cell Lung Cancer, Brain Metastases | Phase 2 | Unknown | Second Affiliated Hospital of Nanchang University | 36 | 2023-12-01 | 2023-11-18 |
| Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases pyrotinib+capecitabine+bevacizumab - Breast Cancer With Brain Metastases | Phase 2 | Unknown | Tongji Hospital | 30 | 2023-11-30 | 2023-12-01 |
| A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases Combination use of SRT with T-DXd - Breast Cancer, Brain Metastases | Phase 2 | Unknown | Fudan University | 17 | 2023-11-01 | 2023-10-18 |
| Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis Tocilizumab Injection - Myasthenia Gravis, Generalized | Phase 2 / Phase 3 | Unknown | Tang-Du Hospital | 64 | 2023-04-01 | 2024-01-22 |
| Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer Camrelizumab or envafolimab - Leptomeningeal Metastasis, Immune Checkpoint Inhibitor | Phase 2 | Unknown | Hebei Medical University | 20 | 2022-05-01 | 2022-05-23 |
| Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC Furmonertinib Mesilate Tablets - Non Small Cell Lung Cancer | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 30 | 2022-04-15 | 2023-04-14 |
| Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors Dexamethasone - Malignant Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Unknown | City of Hope Medical Center | 26 | 2022-04-09 | 2024-09-19 |
| Hippocampal-Sparing Stereotactic Radiosurgery Treatment of Brain Metastases Using CyberKnife Hippocampal-sparing, Stereotactic radiosurgery - Brain Metastases, Radiosurgery | Phase 2 | Unknown | Ottawa Hospital Research Institute | 70 | 2022-04-01 | 2022-02-16 |
| Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer Hypofractionated Stereotactic Radiotherap - Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | First People's Hospital of Hangzhou | 21 | 2022-01-01 | 2022-10-20 |
| The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment HLX208 - Brain Tumor, Primary | Phase 2 | Unknown | Shanghai Henlius Biotech | 40 | 2021-12-23 | 2022-05-03 |
| TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) Trastuzumab, Taxanes, Pertuzumab - HER2-positive Breast Cancer, Brain Metastases | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 120 | 2021-10-01 | 2021-06-02 |
| ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases ARX788 - HER2-positive, Metastatic Breast Cancer | Phase 2 | Unknown | Fudan University | 32 | 2021-07-14 | 2022-06-01 |
| Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI. lazertinib(YH25448) - Lung Neoplasms | Phase 2 | Unknown | Jin Hyoung Kang | 40 | 2021-06-23 | 2022-04-20 |
| Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases Tislelizumab, paclitaxel, Carboplatin - Non-Small Cell Squamous Lung Cancer, Brain Metastases | Phase 2 | Unknown | Sun Yat-sen University | 41 | 2021-06-17 | 2022-01-26 |
| Nimodipine in Vestibular Schwanommas NiMODipine Injectable Solution, Placebo - Vestibular Schwannoma | Phase 2 | Unknown | Medical University of Vienna | 30 | 2021-05-04 | 2023-10-19 |
| the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer Anlotinib - Non-small Cell Lung Cancer, Brain Metastases | Phase 2 | Unknown | Li-kun Chen | 54 | 2021-05-01 | 2021-07-27 |
| Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer Nimotuzumab - Leptomeningeal Metastasis, Lung Cancer | Phase 2 | Unknown | Hui Bu | 30 | 2021-04-19 | 2021-04-20 |
Showing 20 of 129. Sign in to see all of them.
Brain Neoplasms (87) · Central Nervous System Neoplasms (28) · Carcinoma, Non-Small-Cell Lung (24) · Glioblastoma (19) · Breast Neoplasms (12) · Astrocytoma (11) · Gliosarcoma (9) · Glioma (7) · Lung Neoplasms (7) · Neoplasm Metastasis (7) · Oligodendroglioma (7) · Histiocytoma, Malignant Fibrous (6) · Meningeal Carcinomatosis (6) · Fibrosarcoma (5) · Leiomyosarcoma (5)
Nervous System Diseases (129) · Neoplasms by Site (125) · Neoplasms (124) · Central Nervous System Diseases (93) · Brain Diseases (90) · Central Nervous System Neoplasms (90) · Neoplasms by Histologic Type (44) · Neoplasms, Nerve Tissue (40) · Neoplasms, Germ Cell and Embryonal (33) · Neuroectodermal Tumors (32) · Lung Diseases (30) · Neoplasms, Glandular and Epithelial (30) · Respiratory Tract Diseases (30) · Respiratory Tract Neoplasms (30)
Radiotherapy (20) · Temozolomide (13) · Carboplatin (9) · Cisplatin (8) · Bevacizumab (7) · Chemotherapy, Adjuvant (7) · Erlotinib Hydrochloride (6) · Etoposide (6) · Drug Therapy (5) · Pemetrexed (4) · Thiotepa (4) · Vincristine (4) · pyrotinib (4) · Dexamethasone (3) · Filgrastim (3)
Children's Cancer and Leukaemia Group (9) · Fudan University (5) · Sun Yat-sen University (5) · Samsung Medical Center (4) · Second Affiliated Hospital of Nanchang University (4) · Betta Pharmaceuticals Co., Ltd. (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (3) · National Taiwan University Hospital (3) · Rongjie Tao (3) · Copenhagen University Hospital, Rigshospitalet (2) · Direct Therapeutics (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · First People's Hospital of Hangzhou (2) · Guangdong Provincial People's Hospital (2) · Gustave Roussy, Cancer Campus, Grand Paris (2)
China (39) · United States (20) · United Kingdom (9) · France (7) · Ireland (7) · South Korea (7) · Italy (5) · Denmark (4) · Israel (4) · Netherlands (4) · Taiwan (4) · Germany (3) · Poland (3) · Russia (3) · Canada (2)
Liu Anwen, Phd (3) · Andrey S. Bryukhovetskiy, MD (2) · Anthony Michalski, MD (2) · Barry Pizer, MD (2) · David A. Walker (2) · David Ellison, MD (2) · Frank Saran, MD (2) · Gene David Resnick, MD (2) · Jeffrey Raizer, MD (2) · John Fiveash, MD (2) · Roger Taylor, MD (2) · Susan V. Picton, MD (2) · Adam Mamelak, MD (1) · Alba A. Brandes, MD (1)
PMID 25303679, PMID 25789053, PMID 10655437, PMID 11452123, PMID 11937316, PMID 12177103, PMID 12434281, PMID 12750523, PMID 14506149, PMID 15809479, PMID 16011702, PMID 16078267, PMID 16265674, PMID 16510333, PMID 16598416, PMID 16645718, PMID 16757720, PMID 16877732, PMID 17229875, PMID 17374728, PMID 17544337, PMID 17647306, PMID 17894407, PMID 17909941, PMID 18217208, PMID 18577561, PMID 18990510, PMID 19147777, PMID 19801201, PMID 19957326, PMID 19985059, PMID 20694800, PMID 20708924, PMID 20921456, PMID 20974795, PMID 21041710, PMID 21087935, PMID 21171927, PMID 21292687, PMID 21297126, PMID 21297433, PMID 21327862, PMID 21472002, PMID 22012633, PMID 22132908, PMID 22134072, PMID 22179954, PMID 22331797, PMID 22362813, PMID 22487432
2015 (2), 2018 (2), 2005 (1), 2008 (1), 2014 (1), 2017 (1), 2019 (1), P30CA033572 (1), P30CA060553 (1)